(Q38001577)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

The prognostic value of amyloid imaging (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

author name string

Giorgio Gelosa

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

1 reference

11 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

number of pages

13

1 reference

European Journal of Nuclear Medicine and Molecular Imaging

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

1207-1219

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging.

28 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Neuropathologic features of amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Mild cognitive impairment as a diagnostic entity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Mild cognitive impairment: clinical characterization and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Pathways towards and away from Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Accuracy of clinical criteria for AD in the Honolulu-Asia Aging Study, a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Evaluation of the NINCDS-ADRDA criteria in the differentiation of Alzheimer's disease and frontotemporal dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Multimodal techniques for diagnosis and prognosis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Imaging Alzheimer's disease pathology: one target, many ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Monitoring the amyloid beta-peptide in vivo--caveat emptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Interaction of the amyloid imaging tracer FDDNP with hallmark Alzheimer's disease pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Neuropathological stageing of Alzheimer-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

[(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

PET imaging of amyloid deposition in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Microglial activation and amyloid deposition in mild cognitive impairment: a PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Amyloid imaging in mild cognitive impairment subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Frequent amyloid deposition without significant cognitive impairment among the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Imaging beta-amyloid burden in aging and dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

β-Amyloid burden in healthy aging: regional distribution and cognitive consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

The current status of apo E4 as a risk factor for Alzheimer's disease: an epidemiological perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

ApoE promotes the proteolytic degradation of Abeta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Apolipoprotein E, Dementia, and Cortical Deposition of β-Amyloid Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Predictive value of APOE genotyping in incipient Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

The clinical use of structural MRI in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Cognition, reserve, and amyloid deposition in normal aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Detection of amyloid in Alzheimer's disease with positron emission tomography using [11C]AZD2184.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6- (2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

PET of brain amyloid and tau in mild cognitive impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Response to Letter from Shin and Lee, entitled "FDDNP PET patterns in nondemented populations"

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Multitracer PET imaging of amyloid plaques and neurofibrillary tangles in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Clinical applications of PET amyloid imaging: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

21 January 2018

Brain amyloid imaging

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Biomarkers for early detection of Alzheimer pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Burden of Alzheimer's disease: population-based estimates and projections for New Zealand, 2006-2031

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00259-012-2108-X

Clinicopathologic correlates in Alzheimer disease: assessment of clinical and pathologic diagnostic criteria.

21 January 2018

1 reference

12 December 2020

Combination of biomarkers: PET [18F]flutemetamol imaging and structural MRI in dementia and mild cognitive impairment

1 reference

12 December 2020

Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease

1 reference

12 December 2020

In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET.

1 reference

12 December 2020

[11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease

1 reference

12 December 2020

Age-associated memory impairment: diagnostic criteria and treatment strategies.

1 reference

12 December 2020

Aging, memory, and mild cognitive impairment.

1 reference

12 December 2020

PIB is a non-specific imaging marker of amyloid-beta (Abeta) peptide-related cerebral amyloidosis

1 reference

12 December 2020

Aging-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization.

1 reference

12 December 2020

10.1007/S00259-012-2108-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22491780%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

1 reference